Gene & Cell Therapies: Benefits & Challenges from an Actuarial Perspective
20 February 2024 | 14:00-15:30 CET
Over the past 5 years, gene and cell therapies have gained significant attention in both North America and Europe. These therapies hold tremendous promise, offering potential long-term and possibly permanent cures for previously incurable or untreatable diseases, often with a single dose. However, it’s not without a cost: gene therapies are currently priced in the range of 1-4 million U.S. dollars/euros, which has sparked concerns about affordability and payment responsibility.
In the U.S., where many of the recent drug approvals have taken place, reinsurance has been a commonly used solution, but it has its limitations. Payers, drug manufacturers, and government entities both in the U.S. and EU are diligently working to develop improved payment models to address these challenges and ensure access to these live-changing therapies.
In this web session, we aim to provide a basic introduction to gene and cell therapies, shedding light on the obstacles that lie ahead in terms of access and affordability and the actuary's role in helping to develop solutions.
Your early-bird registration fee is € 100.00 plus 19% VAT for bookings by 9 January 2024. After this date, the fee will be € 140.00 plus 19% VAT.
